CLOZAPINE AND HALOPERIDOL IN A SINGLE‐BLIND CROSS‐OVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA